sorafenib and MEA 2b
sorafenib has been researched along with MEA 2b in 2 studies
Research
Studies (2)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Aller, S; Gosiengfiao, Y; Morgan, E; Popescu, A; Rao, S | 1 |
| Cagan, RL; Dar, AC; Das, TK; Shokat, KM | 1 |
Other Studies
2 other study(ies) available for sorafenib and MEA 2b
| Article | Year |
|---|---|
Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Female; Humans; Multiple Endocrine Neoplasia Type 2b; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Thyroid Neoplasms | 2012 |
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
Topics: Animals; Benzenesulfonates; Cell Transformation, Neoplastic; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Extracellular Signal-Regulated MAP Kinases; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Molecular Targeted Therapy; Multiple Endocrine Neoplasia Type 2b; Niacinamide; Phenylurea Compounds; Polypharmacy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; src-Family Kinases; Survival Rate; Xenograft Model Antitumor Assays | 2012 |